UK Markets open in 1 hr 53 mins

Arrowhead Pharmaceuticals, Inc. (ARWR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
28.00-1.50 (-5.08%)
At close: 04:00PM EST
28.40 +0.40 (+1.43%)
After hours: 07:42PM EST

Arrowhead Pharmaceuticals, Inc.

177 East Colorado Boulevard
Suite 700
Pasadena, CA 91105
United States
626 304 3400
https://arrowheadpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees329

Key executives

NameTitlePayExercisedYear born
Dr. Christopher R. Anzalone Ph.D.CEO, Pres & Director1.68M6.71M1969
Mr. Kenneth A. MyszkowskiChief Financial Officer729.77k3.78M1966
Mr. Patrick O'Brien J.D., PharmDCOO & Gen. Counsel733.13k7.49M1964
Dr. James C. Hamilton M.D., MBASr. VP of Discovery & Translational Medicine673.45kN/A1979
Dr. Javier San Martin M.D.Chief Medical Officer658.48kN/A1965
Dr. Mark M. Davis Ph.D.Founder and Founder & Director of Insert Therapeutics Inc & CalandoN/AN/AN/A
Dr. Vincent Anzalone CFAHead of Investor Relations & VPN/AN/AN/A
Mr. Howard LovyDirector of CommunicationsN/AN/AN/A
Dr. Mark SeefeldHead of Toxicology & VPN/AN/A1954
Ms. Tracie OliverChief Commercial OfficerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Corporate governance

Arrowhead Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 October 2022 is 6. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.